Table 1.

Patient demographics and clinical data before the initiation of MTX (0 month), and after 3- and 6-months of therapy.

Patient Characteristics
Visit (months)	0	3	6
Patients, n	66	51	34
Gender, female, n (%)	48 (73)	33 (65)	22 (65)
Age, yr, median [IQR]	11.5 [5.4, 14.4]	10.9 [5.3, 13.8]	10.3 [5.5, 13.9]
ESR, mm/h	16 [9, 35]	9 [7, 21]***	8 [7, 15]***
CRP, mg/L	0.7 [0.5, 1.8]	0.5 [0.5, 1.3]*	0.5 [0.5, 0.6]*
AJC	5 [2, 13]	3 [1, 7]***	1 [0, 5]***
PT-VAS	6 [3, 8]	2 [0.8, 4]***	1 [0.5, 4]***
MD-VAS	5 [3, 7]	2 [0, 4]***	1 [0, 2.5]***
CHAQ	0.5 [0.1, 1.4]	0.12 [0, 0.66]***	0 [0, 0.25]***
JADAS	19 [12, 30]	7 [4, 16.5]***	5 [2, 10.15]***
ACR Pedi < 30, n (%)	---	15 (29)	5 (15)
ACR Pedi > 30, n (%)	---	36 (71)	29 (85)
ACR Pedi > 50, n (%)	---	27 (53)	27 (79)
ACR Pedi > 70, n (%)	---	14 (27)	18 (53)

^*, p < 0.05;

^**, p< 0.01;

^***, p < 0.001 by paired Wilcoxon signed-rank testing.

Erythrocyte sedimentation rate (ESR); c-reactive protein (CRP); active joint count (AJC); patient/parent global assessment of overall well-being (PT-VAS); physician global assessment of disease activity (MD-VAS); Childhood Health Assessment Questionnaire (CHAQ); 71-joint count Juvenile Arthritis Disease Activity Score (JADAS); American College of Rheumatology pediatric response criteria (ACR Pedi).